Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Denton

Showing results (341-350 of 484) with videos related to

Pageof 49
Sort By:
The European Respiratory Journal|February 22, 2020
Predictors of progression in systemic sclerosis patients with interstitial lung diseaseOliver Distler, Shervin Assassi, Vincent Cottin, et al.
Matrix Biology : Journal of the International Society for Matrix Biology|August 8, 2007
Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblastsXu Shi-Wen, Elisabetta A Renzoni, Laura Kennedy, et al.
Rheumatology (Oxford, England)|May 18, 2022
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosisChristopher P Denton, Francesco Del Galdo, Dinesh Khanna, et al.
Rheumatology (Oxford, England)|February 1, 2022
Rheumatologists have an important role in the management of interstitial lung disease (ILD): a cross-speciality, multi-centre, UK perspectivePuja Mehta, Rachel K Hoyles, Harsha Gunawardena, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 26, 2023
Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022 European Society of Cardiology and the European Respiratory Society GuidelinesOliver Distler, Diana Bonderman, J Gerry Coghlan, et al.
Clinical and Experimental Rheumatology|February 27, 2026
Nintedanib in systemic sclerosis-associated interstitial lung disease: real-world cohort study on tolerability and discontinuationPunchalee Kaenmuang, Nina R Goldman, Arthihai Srirangan, et al.
Seminars in Arthritis and Rheumatism|February 6, 2025
Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based studyJulia Spierings, Giulia Bandini, Yannick Allanore, et al.
The Journal of Rheumatology|November 3, 2017
Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group StudyVivien M Hsu, Christopher P Denton, Robyn T Domsic, et al.
The Lancet. Rheumatology|October 17, 2025
Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in systemic sclerosisJohn D Pauling, Yannick Allanore, Maya H Buch, et al.
Rheumatology (Oxford, England)|February 5, 2025
A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosisChristopher P Denton, Otylia Kowal-Bielecka, Susanna M Proudman, et al.
Pageof 49

Showing results (341-350 of 484) with videos related to

Sort By:
Pageof 49
The European Respiratory Journal|February 22, 2020
Predictors of progression in systemic sclerosis patients with interstitial lung diseaseOliver Distler, Shervin Assassi, Vincent Cottin, et al.
Matrix Biology : Journal of the International Society for Matrix Biology|August 8, 2007
Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblastsXu Shi-Wen, Elisabetta A Renzoni, Laura Kennedy, et al.
Rheumatology (Oxford, England)|May 18, 2022
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosisChristopher P Denton, Francesco Del Galdo, Dinesh Khanna, et al.
Rheumatology (Oxford, England)|February 1, 2022
Rheumatologists have an important role in the management of interstitial lung disease (ILD): a cross-speciality, multi-centre, UK perspectivePuja Mehta, Rachel K Hoyles, Harsha Gunawardena, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 26, 2023
Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022 European Society of Cardiology and the European Respiratory Society GuidelinesOliver Distler, Diana Bonderman, J Gerry Coghlan, et al.
Clinical and Experimental Rheumatology|February 27, 2026
Nintedanib in systemic sclerosis-associated interstitial lung disease: real-world cohort study on tolerability and discontinuationPunchalee Kaenmuang, Nina R Goldman, Arthihai Srirangan, et al.
Seminars in Arthritis and Rheumatism|February 6, 2025
Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based studyJulia Spierings, Giulia Bandini, Yannick Allanore, et al.
The Journal of Rheumatology|November 3, 2017
Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group StudyVivien M Hsu, Christopher P Denton, Robyn T Domsic, et al.
The Lancet. Rheumatology|October 17, 2025
Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in systemic sclerosisJohn D Pauling, Yannick Allanore, Maya H Buch, et al.
Rheumatology (Oxford, England)|February 5, 2025
A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosisChristopher P Denton, Otylia Kowal-Bielecka, Susanna M Proudman, et al.
Pageof 49